Overcoming Deadly Diseases
A new class of cancer therapies
Improving and Extending Lives
Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up $238 Million Up Front Plus Additional $136.5 Million in Potential Milestones Plus Royalties.
2022 Society of Neuro-Oncology Annual Meeting
Come see us at the 2022 SNO Meeting Nov 17-19 in Tampa, FL. Our full team will be onsite to discuss ONC201, the ACTION study and advances in the treatment of glioma.
- Chimerix Responds to Rubric Capital Managementon November 10, 2022
- Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Updateon November 3, 2022